Want to see PRAX full AI Analyst Report?
PRAX Stock Chart & Stats
$325.30
-$9.50(-2.92%)
At close: 4:00 PM EDT
$325.30
-$9.50(-2.92%)
Day’s Range― - ―
52-Week Range$37.19 - $366.52
Previous Close$315.8
Volume296.03K
Average Volume (3M)493.75K
Market Cap
$8.58B
Enterprise Value$8.52K
Total Cash (Recent Filing)$786.87M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Aug 06, 2026EPS Estimate
-3.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.39
Shares Outstanding27,878,775
10 Day Avg. Volume281,120
30 Day Avg. Volume493,747
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)7.55
Price to Sales (P/S)0.00
P/FCF Ratio-26.63
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$601.59Price Target Upside84.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-15.27
Revenue Forecast (FY)$2.42M
Bulls Say, Bears Say
Bulls Say
Balance Sheet / RunwayPraxis’s $1.4B cash position combined with extremely low debt provides multi-year financial flexibility, enabling continued late-stage development and commercial build without immediate refinancing. This reduces balance-sheet risk and allows focused investment in launches and pivotal readouts through 2028.
Regulatory Progress / NDA AcceptancesAcceptance of two NDAs with fixed PDUFA dates moves key assets from discovery into formal regulatory review and launch preparation. This materially de-risks timing versus earlier stages, aligns commercial investments, and creates a clear pathway to initial product revenues and validation of the company’s precision-CNS strategy.
Strong Clinical Signal (elsunersen)A robust 77% placebo‑adjusted effect in EMBRAVE Part A and FDA Breakthrough designation validate elsunersen’s mechanism and clinical promise in a rare pediatric epilepsy. This strengthens the asset’s scientific moat, can accelerate development/review, and supports premium positioning, partnerships, and durable franchise value if replicated.
Bears Say
High Cash BurnSustained negative operating and free cash flows near -$283M TTM show a structurally high cash burn driven by multiple late‑stage programs and commercial build. Even with current runway, delays in approvals or launches would necessitate additional financing or program cuts, raising dilution and execution risk over the medium term.
No Commercial Revenue / Widening LossesPraxis remains a pre-revenue, clinical‑stage firm with widening net losses, meaning value creation depends entirely on successful approvals or partnerships. Lack of product revenue implies prolonged reliance on capital markets and increases exposure to trial, regulatory, and launch execution risks before self-sustaining cash flows emerge.
Program Execution Risk (vormatrigine)POWER1’s primary endpoint miss and the subsequent pause of POWER2 introduce substantive program risk for vormatrigine, potentially reducing near-term pipeline value. Reassessment may require additional studies, raise costs, and delay commercialization, concentrating execution risk on fewer assets and stretching management focus.
Praxis Precision Medicines News
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $37.19 and its highest was $366.52 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Praxis Precision Medicines’s market cap is $8.58B.
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on May 07, 2026. The company reported -$3.2 earnings per share for the quarter, beating the consensus estimate of -$3.589 by $0.389.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -3.67.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 27,878,775 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$3.2 in its last earnings report, beating expectations of -$3.589. Following the earnings report the stock price went down -1.417%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Currently, no hedge funds are holding shares in PRAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Praxis Precision Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$601.59 (84.93% Upside)
$601.59 (84.93% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 832.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
460.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
205.01%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
PRAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and clinical momentum: two NDAs accepted with PDUFA dates, rapid completion of a key EMBOLD study, an impressive 77% placebo‑adjusted seizure reduction in EMBRAVE Part A, multiple upcoming pivotal readouts, and a strengthened balance sheet ($1.4B, +51% vs. year‑end). Management is heavily investing in commercialization and late‑stage development (Q1 operating cash use +62% YoY), which raises short‑term cash burn and execution risk. Regulatory timing, heterogeneous populations in broad DEE, and U.S. pricing dynamics are notable uncertainties but are framed as manageable. On balance, the positive clinical data, regulatory progress, and substantial cash runway outweigh the cost and execution risks.View all PRAX earnings summariesPRAX Stock 12 Month Forecast
Average Price Target
$601.59
▲(84.93% Upside)
Technical Analysis
ARS Pharmaceuticals
―
AbCellera Biologics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
8.07% Insiders
25.19% Mutual Funds
0.25% Other Institutional Investors
49.68% Public Companies and Individual Investors